Study #2024-1475
A first-in-human (FiH) study of IK-595, an oral dual MEK/RAF inhibitor, in patients with RAS-or RAF-altered advanced solid tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
IK-595
Description
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Study phase:
Phase I
Physician name:
John Paul Shen
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.